Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study.

摘要: PURPOSETo determine in a prospective randomized trial whether high-dose orally administered medroxy-progesterone acetate (MPA) was superior to tamoxifen patients with recurrent or metastatic breast cancer who had received no prior endocrine therapy either the adjuvant advanced setting.PATIENTS AND METHODSPatients initially 20 mg/d MPA 1 g/d orally. At time of disease progression, were crossed over other regimen. Eligibility required be age > = 18 years, performance status 0 3, and estrogen receptor (ER)- progesterone (PR)-positive unknown.RESULTSOne hundred eighty-two eligible entered 166 assessable for response. Complete plus partial response rates 17% 34%, respectively (P .01). Patients bone metastases significantly higher rate compared (33% v 13%). Median treatment failure 5.5 months ...